Mallinckrodt (MNK) Getting Somewhat Favorable News Coverage, Accern Reports

News headlines about Mallinckrodt (NYSE:MNK) have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mallinckrodt earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.1257982580572 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the headlines that may have impacted Accern’s scoring:

How to Become a New Pot Stock Millionaire

Several analysts have recently commented on MNK shares. Leerink Swann assumed coverage on Mallinckrodt in a research note on Tuesday, January 2nd. They issued a “market perform” rating and a $26.00 target price for the company. Cantor Fitzgerald set a $42.00 price target on Mallinckrodt and gave the company a “buy” rating in a research note on Monday, January 1st. ValuEngine downgraded Mallinckrodt from a “hold” rating to a “sell” rating in a research note on Monday, April 2nd. SunTrust Banks assumed coverage on Mallinckrodt in a research note on Wednesday, April 11th. They set a “hold” rating and a $15.00 price target for the company. Finally, Canaccord Genuity set a $20.00 price target on Mallinckrodt and gave the company a “hold” rating in a research note on Tuesday, March 6th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have given a buy rating to the company. Mallinckrodt presently has a consensus rating of “Hold” and a consensus price target of $33.89.

Mallinckrodt stock opened at $14.04 on Friday. Mallinckrodt has a 52 week low of $13.32 and a 52 week high of $49.12. The company has a current ratio of 2.18, a quick ratio of 1.85 and a debt-to-equity ratio of 0.98. The company has a market cap of $1,208.04, a price-to-earnings ratio of 1.87, a PEG ratio of 0.35 and a beta of 1.12.

Mallinckrodt (NYSE:MNK) last posted its earnings results on Tuesday, February 27th. The company reported $2.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.29. Mallinckrodt had a net margin of 66.25% and a return on equity of 13.43%. The firm had revenue of $792.30 million for the quarter, compared to analysts’ expectations of $769.91 million. During the same quarter last year, the firm earned $1.91 EPS. The company’s quarterly revenue was down 4.5% compared to the same quarter last year. sell-side analysts expect that Mallinckrodt will post 6.16 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by Week Herald and is the property of of Week Herald. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at

About Mallinckrodt

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Insider Buying and Selling by Quarter for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with's FREE daily email newsletter.

Leave a Reply